Nutrients and Drugs in Alzheimer’s Disease: Harnessing Antioxidants

Alzheimer’s disease (AD) has been associated with various types of food and drugs. First, we review the nutrients commonly associated with AD in the literature. Then, we query PubMed citations for the co-occurrence of AD with foods and drugs, using a list of 217,776 molecules. Significantly, AD is found to be associated with prescription drugs, potential therapies, diagnostic agents of amyloid β (Aβ) and tau, potential biomarkers, inducers of AD in animal models, as well as drug scaffold moieties. Prescription drugs include rivastigmine (70.7%), donepezil (67.9%), galantamine (56.5%), tacrine (55.8%), physostigmine (6.5%), memantine (46.2%), selegiline (8.8%), and flurbiprofen (4.5%). Potential therapies include docosahexaenoic acid (3.5%), curcumin (4.6%), rosmarinic acid (3.6%), epigallocatechin (3.1%), resveratrol (3.3%), choline (4.5%), D-serine (4.4%), and D-aspartic acid (4.0%). Diagnostic agents include flortaucipir (39.5%) and exametazime (8.8%). Potential biomarkers include Aβ (81.1%), 24-hydroxycholesterol (38.1%), hydroxynonenal (6.2%), homocysteine (3.7%), and 3-nitrotyrosine (3.0%). Disease inducers include scopolamine (9.3%), mecamylamine (3.2%), α-bungarotoxin (3.0%), ibotenic acid (6.4%), okadaic acid (5.5%), quinolinic acid (4.9%), and streptozocin (3.8%). Drug scaffolds include aniline (5.1%), piperidine (4.9%), stilbene (3.9%), and benzofurane (3.0%). Notably, we classify the molecules according to their role in AD. Our study emphasizes the nutritional value of antioxidants, choline, D-serine, and D-aspartic acid in the prevention of AD. Furthermore, our study promulgates vitamin B, which lowers high homocysteine levels associated with dementia. This study is important because it shows how the foods we eat and the medicines we take influence the risk and progression of AD. By scanning huge amounts of medical research, we identified nutrients (like plant compounds such as those in green tea and turmeric) that help protect the brain, as well as drugs that can be repurposed for treatment. Since Alzheimer’s has no cure and is becoming more common worldwide, these findings highlight that diet, together with smarter drug use, can play a big role in preventing or slowing the disease.

Authors

Institutions

Publication Details

Journal
International journal of Nutrition Pharmacology Neurological Diseases
Published
2025-10-01
DOI
https://doi.org/10.4103/ijnpnd.ijnpnd_123_25
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nutrients and Drugs in Alzheimer’s Disease: Harnessing Antioxidants

Abraham O. Samson, Pnina Frankel, Naamah Bloch, Michal Shteinberg et al.
International journal of Nutrition Pharmacology Neurological Diseases
Alzheimer's disease research and treatments
article

Nutrients and Drugs in Alzheimer’s Disease: Harnessing Antioxidants

Abraham O. Samson, Pnina Frankel, Naamah Bloch, Michal Shteinberg, Karin Ben Zaken, Lior Segev, Baruh Polis, Trishna Saha, Samuel Mesfin, Ibrahim O. Sawaid, Rahaf Ezzy, Tehila Nissim
article en

Abstract

Alzheimer’s disease (AD) has been associated with various types of food and drugs. First, we review the nutrients commonly associated with AD in the literature. Then, we query PubMed citations for the co-occurrence of AD with foods and drugs, using a list of 217,776 molecules. Significantly, AD is found to be associated with prescription drugs, potential therapies, diagnostic agents of amyloid β (Aβ) and tau, potential biomarkers, inducers of AD in animal models, as well as drug scaffold moieties. Prescription drugs include rivastigmine (70.7%), donepezil (67.9%), galantamine (56.5%), tacrine (55.8%), physostigmine (6.5%), memantine (46.2%), selegiline (8.8%), and flurbiprofen (4.5%). Potential therapies include docosahexaenoic acid (3.5%), curcumin (4.6%), rosmarinic acid (3.6%), epigallocatechin (3.1%), resveratrol (3.3%), choline (4.5%), D-serine (4.4%), and D-aspartic acid (4.0%). Diagnostic agents include flortaucipir (39.5%) and exametazime (8.8%). Potential biomarkers include Aβ (81.1%), 24-hydroxycholesterol (38.1%), hydroxynonenal (6.2%), homocysteine (3.7%), and 3-nitrotyrosine (3.0%). Disease inducers include scopolamine (9.3%), mecamylamine (3.2%), α-bungarotoxin (3.0%), ibotenic acid (6.4%), okadaic acid (5.5%), quinolinic acid (4.9%), and streptozocin (3.8%). Drug scaffolds include aniline (5.1%), piperidine (4.9%), stilbene (3.9%), and benzofurane (3.0%). Notably, we classify the molecules according to their role in AD. Our study emphasizes the nutritional value of antioxidants, choline, D-serine, and D-aspartic acid in the prevention of AD. Furthermore, our study promulgates vitamin B, which lowers high homocysteine levels associated with dementia. This study is important because it shows how the foods we eat and the medicines we take influence the risk and progression of AD. By scanning huge amounts of medical research, we identified nutrients (like plant compounds such as those in green tea and turmeric) that help protect the brain, as well as drugs that can be repurposed for treatment. Since Alzheimer’s has no cure and is becoming more common worldwide, these findings highlight that diet, together with smarter drug use, can play a big role in preventing or slowing the disease.

International journal of Nutrition Pharmacology Neurological DiseasesVol. 15(4)
Sunnybrook Health Science Centre (CA), Bar-Ilan University (IL), University of Toronto (CA), Health Sciences Centre (CA)
Openalex Percentile: Top 53%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.